A detailed history of Geode Capital Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,859,232 shares of NBIX stock, worth $236 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,859,232
Previous 1,819,622 2.18%
Holding current value
$236 Million
Previous $251 Million 14.55%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$114.58 - $153.15 $4.54 Million - $6.07 Million
39,610 Added 2.18%
1,859,232 $214 Million
Q2 2024

Aug 09, 2024

BUY
$130.86 - $143.19 $13.9 Million - $15.2 Million
105,908 Added 6.18%
1,819,622 $251 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $11.8 Million - $13 Million
90,590 Added 5.58%
1,713,714 $236 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $7.27 Million - $9.09 Million
68,494 Added 4.41%
1,623,124 $214 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $2.94 Million - $3.66 Million
31,222 Added 2.05%
1,554,630 $175 Million
Q2 2023

Aug 11, 2023

BUY
$89.53 - $104.87 $7.85 Million - $9.19 Million
87,671 Added 6.11%
1,523,408 $144 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $4.43 Million - $5.79 Million
47,042 Added 3.39%
1,435,737 $145 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $7.58 Million - $9.02 Million
71,001 Added 5.39%
1,388,695 $166 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $3.41 Million - $4 Million
37,089 Added 2.9%
1,317,694 $140 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $260,262 - $343,640
-3,434 Reduced 0.27%
1,280,605 $125 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $3.37 Million - $4.41 Million
46,491 Added 3.76%
1,284,039 $120 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $2.02 Million - $2.69 Million
25,327 Added 2.09%
1,237,548 $105 Million
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $783,117 - $899,885
9,087 Added 0.76%
1,212,221 $116 Million
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $2.11 Million - $2.42 Million
23,626 Added 2.0%
1,203,134 $117 Million
Q1 2021

May 12, 2021

BUY
$87.57 - $119.4 $4.72 Million - $6.44 Million
53,898 Added 4.79%
1,179,508 $115 Million
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $5.13 Million - $6.39 Million
59,008 Added 5.53%
1,125,610 $108 Million
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $4.08 Million - $5.73 Million
-42,408 Reduced 3.82%
1,066,602 $102 Million
Q2 2020

Aug 13, 2020

BUY
$85.09 - $130.36 $3.1 Million - $4.74 Million
36,376 Added 3.39%
1,109,010 $135 Million
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $2.81 Million - $4.26 Million
37,404 Added 3.61%
1,072,634 $92.8 Million
Q4 2019

Feb 13, 2020

BUY
$86.8 - $118.57 $4.52 Million - $6.17 Million
52,052 Added 5.29%
1,035,230 $111 Million
Q3 2019

Nov 12, 2019

BUY
$83.82 - $101.5 $574,502 - $695,681
6,854 Added 0.7%
983,178 $88.6 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $1.96 Million - $2.48 Million
27,195 Added 2.87%
976,324 $82.4 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $2.9 Million - $3.83 Million
41,837 Added 4.61%
949,129 $83.6 Million
Q4 2018

Feb 13, 2019

BUY
$68.32 - $124.36 $2.49 Million - $4.54 Million
36,508 Added 4.19%
907,292 $64.8 Million
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $3.32 Million - $4.23 Million
33,581 Added 4.01%
870,784 $107 Million
Q2 2018

Aug 14, 2018

BUY
$75.3 - $105.99 $3.9 Million - $5.5 Million
51,850 Added 6.6%
837,203 $82.2 Million
Q1 2018

May 15, 2018

BUY
$75.88 - $92.43 $1.71 Million - $2.08 Million
22,518 Added 2.95%
785,353 $65.1 Million
Q4 2017

Feb 13, 2018

BUY
$58.53 - $77.59 $722,669 - $958,003
12,347 Added 1.65%
762,835 $59.2 Million
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $1.64 Million - $2.09 Million
34,097 Added 4.76%
750,488 $46 Million
Q2 2017

Aug 14, 2017

BUY
N/A
716,391
716,391 $33 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.